tbuckley/cabot-search huggingface dataset:
Orthostatic Hypotension, Hypertension Treatment, and Cardiovascular Disease
Authors: Stephen P. Juraschek, Jiun-Ruey Hu, Jennifer L. Cluett, Anthony M. Ishak, Carol Mita, Lewis A. Lipsitz, Lawrence J. Appel, Nigel S. Beckett, Ruth L. Coleman, William C. Cushman, Barry R. Davis, Greg Grandits, Rury R. Holman, Edgar R. Miller, Ruth Peters, Jan A. Staessen, Addison A. Taylor, Lutgarde Thijs, Jackson T. Wright, Kenneth J. Mukamal
Journal: JAMA (2023)

Importance There are ongoing concerns about the benefits of intensive vs standard blood pressure (BP) treatment among adults with orthostatic hypotension or standing hypotension. Objective To determine the effect of a lower BP treatment goal or active therapy vs a standard BP treatment goal or placebo on cardiovascular disease (CVD) or all-cause mortality in strata of baseline orthostatic hypotension or baseline standing hypotension. Data Sources Individual participant data meta-analysis based on a systematic review of MEDLINE, EMBASE, and CENTRAL databases through May 13, 2022. Study Selection Randomized trials of BP pharmacologic treatment (more intensive BP goal or active agent) with orthostatic hypotension assessments. Data Extraction and Synthesis Individual participant data meta-analysis extracted following PRISMA guidelines. Effects were determined using Cox proportional hazard models using a single-stage approach. Main Outcomes and Measures Main outcomes were CVD or all-cause mortality. Orthostatic hypotension was defined as a decrease in systolic BP of at least 20 mm Hg and/or diastolic BP of at least 10 mm Hg after changing position from sitting to standing. Standing hypotension was defined as a standing systolic BP of 110 mm Hg or less or standing diastolic BP of 60 mm Hg or less. Results The 9 trials included 29 235 participants followed up for a median of 4 years (mean age, 69.0 [SD, 10.9] years; 48% women). There were 9% with orthostatic hypotension and 5% with standing hypotension at baseline. More intensive BP treatment or active therapy lowered risk of CVD or all-cause mortality among those without baseline orthostatic hypotension (hazard ratio [HR], 0.81; 95% CI, 0.76-0.86) similarly to those with baseline orthostatic hypotension (HR, 0.83; 95% CI, 0.70-1.00; P = .68 for interaction of treatment with baseline orthostatic hypotension). More intensive BP treatment or active therapy lowered risk of CVD or all-cause mortality among those without baseline standing hypotension (HR, 0.80; 95% CI, 0.75-0.85), and nonsignificantly among those with baseline standing hypotension (HR, 0.94; 95% CI, 0.75-1.18). Effects did not differ by baseline standing hypotension ( P = .16 for interaction of treatment with baseline standing hypotension). Conclusions and Relevance In this population of hypertension trial participants, intensive therapy reduced risk of CVD or all-cause mortality regardless of orthostatic hypotension without evidence for different effects among those with standing hypotension.
Treating Hypertension in Patients With Orthostatic Hypotension
Authors: James Brian Byrd, John D. Bisognano, Robert D. Brook
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry
Authors: Juan José Lluch-Galcerá, Jose Manuel Carrascosa, Alicia González-Quesada, Raquel Rivera-Díaz, Antonio Sahuquillo-Torralba, Mar Llamas-Velasco, Francisco José Gómez-García, Enrique Herrera-Acosta, Pablo de la Cueva, Ofelia Baniandrés-Rodríguez, Jose Luis Lopez-Estebaranz, Isabel Belinchón, Marta Ferrán, Almudena Mateu, Lourdes Rodríguez, Josep Riera-Monroig, M Teresa Abalde-Pintos, Gregorio Carretero, Carmen García-Donoso, Conrad Pujol-Marco, Elena Del Alcázar, Cristina Santamaría-Domínguez, Jorge Alonso Suárez-Pérez, Lula María Nieto-Benito, Diana Patricia Ruiz-Genao, Laura Salgado-Boquete, Miguel Ángel Descalzo, Ignacio García-Doval
Journal: British Journal of Dermatology (2023)

Abstract Background Safety is an important consideration in decisions on treatment for patients with moderate-to-severe psoriasis and the study of drug safety is the main purpose of the BIOBADADERM registry. The combination of a biologic agent and a conventional systemic drug [generally methotrexate (MTX)] is a common treatment in clinical practice. However, there is a paucity of evidence from real-world practice on the safety of such combination regimens in the treatment of psoriasis. Objectives The primary objective of this study was to ascertain whether the use of regimens combining biologic drugs with MTX in the management of moderate-to-severe psoriasis increases the risk of adverse events (AEs) or serious AEs (SAEs). We compared monotherapy using tumour necrosis factor (TNF), interleukin (IL)-17 and IL-23 inhibitors with the use of the same drugs in combination with MTX. Methods Using data from the BIOBADADERM registry, we compared biologic monotherapies with therapies that were combined with MTX. We estimated adjusted incidence rate ratios (aIRR) using a random effects Poisson regression with 95% confidence intervals for all AEs, SAEs, infections and serious infections and other AEs by system organ class. Results We analysed data from 2829 patients and 5441 treatment cycles, a total of 12 853 patient-years. The combination of a biologic with MTX was not associated with statistically significant increases in overall risk of AEs or SAEs in any treatment group. No increase in the total number of infections or serious infections in patients receiving combined therapy was observed for any group. However, treatment with a TNF inhibitor combined with MTX was associated with an increase in the incidence of gastrointestinal AEs (aIRR 2.50, 95% CI 1.57–3.98; P &amp;lt; 0.002). Conclusions The risk of AEs and SAEs was not significantly increased in patients with moderate-to-severe psoriasis receiving different classes of biologic drugs combined with MTX compared with those on biologic monotherapy.
Hemodynamic Reactivity to Mental Stress in Patients With Coronary Artery Disease
Authors: Kasra Moazzami, Brian Cheung, Samaah Sullivan, Anish Shah, Zakaria Almuwaqqat, Ayman Alkhoder, Puja K. Mehta, Brad D. Pearce, Amit J. Shah, Afif Martini, Malik Obideen, Jonathon Nye, J. Douglas Bremner, Viola Vaccarino, Arshed A. Quyyumi
Journal: JAMA Network Open (2023)

Importance The clinical significance of hemodynamic reactivity to mental stress in the population with coronary artery disease (CAD) is unclear. Objective To investigate the association between hemodynamic reactivity to mental stress and the risk of adverse cardiovascular events in patients with stable CAD. Design, Setting, and Participants This cohort study included individuals with stable CAD from 2 prospective studies from a university-based hospital network: the Mental Stress Ischemia Prognosis Study (MIPS) and the Myocardial Infarction and Mental Stress Study 2 (MIMS2). Participants were enrolled between June 2011 and March 2016 and followed up for a median of 6.0 (IQR, 5.6-6.0) years in MIPS and 4.6 (IQR, 3.8-5.3) years in MIMS2. Data were analyzed from December 1, 2022, to February 15, 2023. Exposures The rate-pressure product (RPP) was calculated as the mean systolic blood pressure times the mean heart rate at rest. Rate-pressure product reactivity was calculated as the maximum RPP during a standardized mental stress test minus the RPP at rest. Main Outcomes and Measures The primary outcome was a composite of cardiovascular death or nonfatal myocardial infarction. The secondary end point additionally included hospitalizations for heart failure. Results From the total of 938 individuals from the pooled cohort (mean [SD] age, 60.2 [10.1] years; 611 [65.1%] men), 631 participated in MIPS and 307 in MIMS2. A total of 373 individuals (39.8%) were Black, 519 (55.3%) were White, and 46 (4.9%) were of unknown race or ethnicity. The RPP increased by a mean (SD) of 77.1% (23.1%) during mental stress (mean [SD] absolute change, 5651 [2878]). For every SD decrease in RPP reactivity with mental stress, the adjusted hazard ratios for the primary and secondary end points were 1.30 (95% CI, 1.04-1.72) and 1.30 (95% CI, 1.06-1.56), respectively, in MIPS and 1.41 (95% CI, 1.06-1.97) and 1.21 (95% CI, 1.02-1.60), respectively, in MIMS2. In the pooled sample, when RPP reactivity to mental stress was added to a model including traditional clinical risk characteristics, model discrimination for adverse events improved (increase in C statistic of 5% for the primary end point; P = .009). Conclusions and Relevance In this cohort study of individuals with stable CAD, a blunted cardiovascular reactivity to mental stress was associated with adverse outcomes. Future studies are needed to assess the clinical utility of mental stress reactivity testing in this population.
OSR1 disruption contributes to uterine factor infertility via impaired Müllerian duct development and endometrial receptivity
Authors: Adriana Lofrano-Porto, Sidney Alcântara Pereira, Andrew Dauber, Jordana C.B. Bloom, Audrey N. Fontes, Naomi Asimow, Olívia Laquis de Moraes, Petra Ariadne T. Araujo, Ana Paula Abreu, Michael H. Guo, Silviene F. De Oliveira, Han Liu, Charles Lee, Wendy Kuohung, Michella S. Coelho, Rona S. Carroll, Rulang Jiang, Ursula B. Kaiser
Journal: Journal of Clinical Investigation (2023)

Three sisters, born from consanguineous parents, manifested a unique Müllerian anomaly characterized by uterine hypoplasia with thin estrogen-unresponsive endometrium and primary amenorrhea, but with spontaneous tubal pregnancies. Through whole-exome sequencing followed by comprehensive genetic analysis, a missense variant was identified in the OSR1 gene. We therefore investigated OSR1/OSR1 expression in postpubertal human uteri, and the prenatal and postnatal expression pattern of Osr1/Osr1 in murine developing Müllerian ducts (MDs) and endometrium, respectively. We then investigated whether Osr1 deletion would affect MD development, using WT and genetically engineered mice. Human uterine OSR1/OSR1 expression was found primarily in the endometrium. Mouse Osr1 was expressed prenatally in MDs and Wolffian ducts (WDs), from rostral to caudal segments, in E13.5 embryos. MDs and WDs were absent on the left side and MDs were rostrally truncated on the right side of E13.5 Osr1-/- embryos. Postnatally, Osr1 was expressed in mouse uteri throughout their lifespan, peaking at postnatal days 14 and 28. Osr1 protein was present primarily in uterine luminal and glandular epithelial cells and in the epithelial cells of mouse oviducts. Through this translational approach, we demonstrated that OSR1 in humans and mice is important for MD development and endometrial receptivity and may be implicated in uterine factor infertility.
Rational Engineering of a Multifunctional DNA Assembly for Enhanced Antibacterial Efficacy and Accelerated Wound Healing
Authors: Shanshan Yu, Jing Wang, Meijuan Liang, Jinhua Shang, Yingying Chen, Xiaoqing Liu, Dengpeng Song, Fuan Wang
Journal: Advanced Healthcare Materials (2023)

DNA-based assemblies hold immense prospects for antibacterial application, yet are constrained by their poor specificity and deficient antibacterial delivery. Herein, the fabrication of a versatile rolling circle amplification (RCA)-sustained DNA assembly is reported, encoding simultaneously with multivalent aptamers and tandem antibacterial agents, for target-specific and efficient antibacterial application. In the compact RCA-sustained antibacterial platform, the facilely organized multivalent aptamers guarantee the target bacteria-specific delivery of sufficient antibacterial agents which is assembled through DNA-stabilizing silver nanostructures. It is shown that the biocompatible DNA system could enhance bacteria elimination and simultaneously facilitate wound healing in vivo. By virtue of the programmable RCA assembly, the present RCA-sustained system provides a highly modular and scalable approach to design versatile multifunctional therapeutic systems.
Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma
Authors: Philip Clingan, Rahul Ladwa, Daniel Brungs, Dean Laurence Harris, Margaret McGrath, Susan Arnold, Jermaine Coward, Samuel Fourie, Andriy Kurochkin, Daniel R Malan, Andrew Mant, Vinay Sharma, Hong Shue, Andrea Tazbirkova, Miguel-Angel Berciano-Guerrero, Chaiyut Charoentum, Stéphane Dalle, Arunee Dechaphunkul, Oleksandr Dudnichenko, Piotr Koralewski, Iwona Lugowska, Henri Montaudié, Eva Muñoz-Couselo, Virote Sriuranpong, James Oliviero, Jayesh Desai
Journal: Journal for ImmunoTherapy of Cancer (2023)

Background Programmed cell death receptor-1 (PD-1)-blocking antibodies are approved to treat metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) cases ineligible for curative surgery or radiation. Notwithstanding, some patients experience inadequate responses or severe immune-related adverse events (AEs), indicating the need for improved therapies. Cosibelimab is a high-affinity programmed cell death-ligand 1 (PD-L1)-blocking antibody that activates innate and adaptive immunity by blocking PD-L1 interaction with PD-1 and B7-1 receptors. It is an unmodified immunoglobulin G1 subtype with a functional Fc domain capable of inducing antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Here, we present results of the pivotal study of patients with metastatic CSCC from an open-label, multicenter, multiregional, multicohort, phase 1 trial of cosibelimab. Methods In this trial, participants with metastatic CSCC received cosibelimab 800 mg intravenously every 2 weeks. Primary endpoint was objective response rate (ORR) by independent central review using Response Evaluation Criteria in Solid Tumors, V.1.1. Secondary endpoints included duration of response (DOR) and safety. Results Objective response was observed in 37 of 78 participants (47.4% (95% CI: 36.0% to 59.1%)), with median follow-up of 15.4 months (range: 0.4 to 40.5) as of data cut-off. Median DOR was not reached (range: 1.4+ to 34.1+ months), with response ongoing in 73.0% of participants. Common treatment-emergent AEs (≥15%) were fatigue (26.9%), rash (16.7%), and anemia (15.4%). Eighteen participants (23.1%) experienced immune-related AEs (grade 3: n=2 (2.6%); no grade 4/5). No treatment-related deaths were reported. Conclusions Cosibelimab demonstrated clinically meaningful ORR and DOR and was associated with a manageable safety profile. Trial registration number NCT03212404 .
Clinical and regulatory development strategies for Shigella vaccines intended for children younger than 5 years in low-income and middle-income countries
Authors: Birgitte K Giersing, Richard Isbrucker, David C Kaslow, Marco Cavaleri, Norman Baylor, Diadié Maiga, Patricia B Pavlinac, Mark S Riddle, Gagandeep Kang, Calman A MacLennan
Journal: The Lancet Global Health (2023)
TCT-451 Use of CrossBoss in Chronic Total Occlusion Percutaneous Coronary Intervention
Authors: Judit Karacsonyi, Athanasios Rempakos, Michaella Alexandrou, Salman Allana, Spyridon Kostantinis, Bahadir Simsek, Ahmed Al-Ogaili, Khaldoon Alaswad, Dimitri Karmpaliotis, Ajay Kirtane, Margaret McEntegart, Farouc Jaffer, James Choi, Paul Poommipanit, Basem Elbarouni, Sevket Gorgulu, Ahmed ElGuindy, Nidal Abi Rafeh, Omer Goktekin, Lorenzo Azzalini, Imre Ungi, Bavana Rangan, Olga Mastrodemos, Yader Sandoval, M. Nicholas Burke, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2023)
TCT-533 Long-Term Clopidogrel Monotherapy Versus Aspirin Monotherapy in Real-world Nationwide Population Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents: Efficacy and Safety Comparison
Authors: Jong-Seok Lee, Jin-Seok Kim, Jeong-Cheon Ahn, Sunwon Kim
Journal: Journal of the American College of Cardiology (2023)
TCT-514 Safety and Efficacy of 19 Stent Strategies in Percutaneous Coronary Intervention: A Trial-Sequential, Influential, Bivariate and Network Meta-Analysis
Authors: Waqas Ullah, Harigopal Sandhyavenu, Syeda Ramsha Zaidi, Mileydis Alonso, Muhammad Atif Khan, Irfan Ullah, Farah Yasmin, Aravind Reddy Polam, Salman Zahid
Journal: Journal of the American College of Cardiology (2023)
TCT-573 Novel Coronary Access Techniques for TAV-in-TAV With Balloon and Self-Expandable Valves
Authors: Francesco Giannini, Alessandro Beneduce, Jonathan Curio, Adriana Zlahoda-Huzior, David Meier, Janarthanan Sathananthan, Dariusz Dudek, Arif Khokhar
Journal: Journal of the American College of Cardiology (2023)
TCT-462 Immediate Versus Staged Complete Revascularization Angina-Related Quality of Life in Patients Presenting With Acute Coronary Syndrome and Multivessel Coronary Disease: Results From the Prospective, Open-Label, Noninferiority, Randomized BIOVASC trial
Authors: Paul Cummins, Jacob Elscot, Johan Bennett, Giovanni Esposito, Manel Sabate, Roberto Diletti, Eric Boersma, Nicolas Van Mieghem, Wijnand Den Dekker
Journal: Journal of the American College of Cardiology (2023)
TCT-631 Temporal Trends in 1-Year Cause-Specific Mortality After Transcatheter Aortic Valve Replacement: Insights From the STS/ACC TVT Registry
Authors: Dhaval Kolte, Guillaume Marquis-Gravel, Amanda Stebbins, Andrew Vekstein, Andrzej Kosinski, Sreekanth Vemulapalli, Sammy Elmariah
Journal: Journal of the American College of Cardiology (2023)
TCT-490 Sex-Specific Temporal Trends in Incidence and Outcomes of Cardiogenic Shock in Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention
Authors: Kamil Bujak, Przemysław Trzeciak, Mateusz Tajstra, Janina Stępińska, Wojtek Wojakowski, Dariusz Dudek, Adam Witkowski, Robert J. Gil, Jacek Legutko, Marek Gierlotka, Wiktor Kuliczkowski, Mariusz Gąsior
Journal: Journal of the American College of Cardiology (2023)
TCT-610 Predictors of Readmission and Resource Utilization in Transcatheter Aortic Valve Implantation With and Without Mitral Stenosis: A National Readmission Database Study
Authors: Shafaqat Ali, Harshith Thyagaturu, Lalitsiri Atti, Laxman Yeshwant Byreddi, Faryal Farooq, Maan Awad, Matthew Santer, Fadi Khir, Chadi Alraies
Journal: Journal of the American College of Cardiology (2023)
TCT-456 DETECT-DVT: Detroit Evaluation of Thrombectomy and Evaluation of Intravascular Ultrasound in Deep Vein Thrombosis
Authors: Sabina Kumar, Brian Ballard, Samuel Reenders, Chukwuemeka Umeh, Don Tait, Jason Kaplan, Lakshmi Rao, Anila Rao, Zeinab Saghir, Brandon Ballard, Matthew Edwards, Mark Zainea, Jay Mohan
Journal: Journal of the American College of Cardiology (2023)
TCT-622 Native Valve and Neo-Sinus Remodeling Following Transcatheter Aortic Valve Replacement
Authors: Joshua Yoon, Hacina Gill, Julius Jelisejevas, David Meier, Althea Lai, Michael Seidman, Geoffrey Payne, John Webb, Janarthanan Sathananthan, Stephanie Sellers
Journal: Journal of the American College of Cardiology (2023)
TCT-588 Association of Prosthesis Deformation of Balloon-Expandable Transcatheter Aortic Valves With Subclinical Leaflet Thrombosis
Authors: Shubhadarshini Pawar, Vivek Patel, Takashi Nagasaka, Jair Basantes, Dhairya Patel, Tarun Chakravarty, Ofir Koren, Mamoo Nakamura, Wen Cheng, Hasanian Jilaihawi, Aakriti Gupta, Raj Makkar
Journal: Journal of the American College of Cardiology (2023)
TCT-545 Effect of Transcatheter Aortic Valve Replacement on Ascending Aortic Aneurysm Progression in Bicuspid Aortic Valve Patients: A Retrospective Analysis
Authors: Ofir Koren, Vivek Patel, Takashi Nagasaka, Dan Assaf, Shirin Sadri, Robert Naami, Tina Torbati, Daniel Zumerkorn Hassan, Manvir Dhillon, Alon Shechter, Aakriti Gupta, Hasan Jilaihawi, Tarun Chakravarty, Mamoo Nakamura, Wen Cheng, Raj Makkar
Journal: Journal of the American College of Cardiology (2023)
TCT-483 Patients With Previous Cerebrovascular Events Undergoing Transcatheter Aortic Valve Implantation Have More Periprocedural Strokes
Authors: Astrid van Nieuwkerk, Hugo Aarts, Kimberley Hemelrijk, Cristóbal A. Urbano Carrillo, Didier Tchetche, Fabio Brito, Marco Barbanti, Ran Kornowski, Azeem Latib, Augusto D'Onofrio, Flavio Ribichini, Sergio García-Blas, Nicolas Dumonteil, Alexandre Abizaid, Samantha Sartori, Paola D'Errigo, Giuseppe Tarantini, Mattia Lunardi, Katia Orvin, Matteo Pagnesi, George Dangas, Roxana Mehran, Ronak Delewi
Journal: Journal of the American College of Cardiology (2023)
TCT-494 Impact of Access in Mortality in Patients Undergoing TAVI: Insights From a Nationwide Registry
Authors: Anastasios Apostolos, Ioannis Kachrimanidis, George Latsios, Charalampos Liakos, Nikolaos Ktenopoulos, Georgios Katsimagklis, Antonios Pitsis, Vasileios Voudris, Konstantinos Perreas, Vasileios Kollias, Evangelos Pisimisis, Achilles Zacharoulis, Ioannis (John) Kanakakis, Panagiotis Dedeilias, Andreas Synetos, Christoforos Olympios, Konstantinos Toutouzas
Journal: Journal of the American College of Cardiology (2023)
TCT-620 Positive Adaptive Remodeling Effect of the DynamX Bioadaptor in Bioadaptor RCT
Authors: Mark Webster, Shigeru Saito, Stefan Verheye, Holger Nef, Tsunekazu Kakuta, Junji Yajima, Yoshiaki Ito, Takashi Kajiya, Takuo Nakagami
Journal: Journal of the American College of Cardiology (2023)
TCT-544 Sex Disparities in Transcatheter Aortic Valve Replacement Outcomes: An Analysis of the National Readmission Database
Authors: Steven Imburgio, Sowmya Dandu, Ndausung Udongwo, Anton Mararenko, Palak Patel, Daniel Kiss, Jesus Almendral, Joseph Heaton
Journal: Journal of the American College of Cardiology (2023)
TCT-472 Microvascular Function in Patients With Takotsubo Syndrome
Authors: Maayan Konigstein, Aviel Shetrit, Yishay Szekely, Jeremy Ben-Shoshan, Yaron Arbel, Reut Amar Shamir, Ophir Freund, Shmuel Banai
Journal: Journal of the American College of Cardiology (2023)
TCT-461 Suboptimal Lipid-Lowering Treatment After Complex PCI in Contemporary Practice
Authors: Denise Peeters, Jasper Luijkx, Eva Woelders, Peter Damman, Patty Winkler, Wouter Remkes, Arnoud van 't Hof, Robert-Jan Van Geuns
Journal: Journal of the American College of Cardiology (2023)
TCT-569 Balloon- vs Self-Expanding Valve Systems for Failed Small Surgical Aortic Valve Bioprostheses: 1-Year Results of the LYTEN Trial
Authors: Jorge Nuche, Amr Abbas, Victoria Vilalta, Luis Nombela-Franco, Ander Regueiro, Karim Al-Azizi, Ayman Iskander, Lenard Conradi, Jessica Forcillo, Scott Lilly, Alvaro Calabuig Goena, Siamak Mohammadi, Carlos Giuliani, Emilie Pelletier-Beaumont, Philippe Pibarot, Josep Rodes-Cabau
Journal: Journal of the American College of Cardiology (2023)
TCT-510 All-Cause 30-Day Readmission Rates in Patients Undergoing Transcatheter Aortic Valve Replacement
Authors: Arham Pasha, Ronak Bharucha, Hassan Khan, Raheel Khan, Timothy Avino, Usman Najam, Ryan Mackey, Andrew Monte, Gregory Gudleski, Kevin Frodey, Vijay Iyer
Journal: Journal of the American College of Cardiology (2023)